CN110088092B - 化合物，制备方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法 - Google Patents

化合物，制备方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法 Download PDF

Info

Publication number
CN110088092B
CN110088092B CN201780079647.XA CN201780079647A CN110088092B CN 110088092 B CN110088092 B CN 110088092B CN 201780079647 A CN201780079647 A CN 201780079647A CN 110088092 B CN110088092 B CN 110088092B
Authority
CN
China
Prior art keywords
benzimidazol
ethyl
methoxy
ethoxy
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780079647.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110088092A (zh
Inventor
C.鲁施维内克基玛拉斯
H.费利普扎内蒂德阿泽维多
A.马斯加瑞罗
R.瓦坦纳贝达科斯塔
V.弗雷热托瑞斯卢索
E.曼诺西奥德素扎卢索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ache Laboratorios Farmaceuticos SA
Original Assignee
Ache Laboratorios Farmaceuticos SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos SA filed Critical Ache Laboratorios Farmaceuticos SA
Priority to CN202210815568.3A priority Critical patent/CN115181108A/zh
Publication of CN110088092A publication Critical patent/CN110088092A/zh
Application granted granted Critical
Publication of CN110088092B publication Critical patent/CN110088092B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780079647.XA 2016-10-24 2017-10-23 化合物，制备方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法 Active CN110088092B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210815568.3A CN115181108A (zh) 2016-10-24 2017-10-23 化合物及其制备方法、药物组合物和用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRBR1020160248140 2016-10-24
BR102016024814A BR102016024814A2 (pt) 2016-10-24 2016-10-24 composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PCT/BR2017/050320 WO2018076090A1 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210815568.3A Division CN115181108A (zh) 2016-10-24 2017-10-23 化合物及其制备方法、药物组合物和用途

Publications (2)

Publication Number Publication Date
CN110088092A CN110088092A (zh) 2019-08-02
CN110088092B true CN110088092B (zh) 2022-10-04

Family

ID=62023150

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780079647.XA Active CN110088092B (zh) 2016-10-24 2017-10-23 化合物，制备方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法
CN202210815568.3A Pending CN115181108A (zh) 2016-10-24 2017-10-23 化合物及其制备方法、药物组合物和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210815568.3A Pending CN115181108A (zh) 2016-10-24 2017-10-23 化合物及其制备方法、药物组合物和用途

Country Status (21)

Country Link
US (2) US10781182B2 (enExample)
EP (2) EP3529234B1 (enExample)
JP (1) JP7194683B2 (enExample)
KR (1) KR102594251B1 (enExample)
CN (2) CN110088092B (enExample)
AR (1) AR109467A1 (enExample)
AU (1) AU2017351756B2 (enExample)
BR (1) BR102016024814A2 (enExample)
CA (1) CA3042040A1 (enExample)
CL (1) CL2019001105A1 (enExample)
CO (1) CO2019004756A2 (enExample)
DK (1) DK3529234T3 (enExample)
EC (1) ECSP19032963A (enExample)
ES (2) ES3013994T3 (enExample)
FI (1) FI3529234T3 (enExample)
MX (1) MX392990B (enExample)
PE (2) PE20191046A1 (enExample)
PT (1) PT3529234T (enExample)
SG (2) SG10202009001TA (enExample)
UY (2) UY40644A (enExample)
WO (1) WO2018076090A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PT3433256T (pt) 2016-10-24 2019-10-31 Astrazeneca Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento do cancro
KR102246668B1 (ko) 2017-01-30 2021-04-29 아스트라제네카 아베 에스트로겐 수용체 조절인자
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
PE20221838A1 (es) 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276051A (en) * 1991-08-13 1994-01-04 Adir Et Compagnie Arylethylamine compounds
EP0788795A1 (en) * 1994-06-10 1997-08-13 Nauchno-Issledovatelsky Institut Farmakologii Akademii Meditsinskikh Nauk Pharmacologically active 2-mercaptobenzimidazole derivatives
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
CN1922141A (zh) * 2004-02-23 2007-02-28 大日本住友制药株式会社 新的杂环化合物
WO2008032164A2 (en) * 2006-09-12 2008-03-20 Pfizer Products Inc. Benzimidazolone derivatives
WO2008051533A2 (en) * 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Benzimidazole compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5260051A (en) 1990-12-17 1993-11-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising phosphate ester compounds containing a beneficial reagent component
FR2674524B1 (fr) 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
FR2738818B1 (fr) 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
WO1998025606A1 (en) 1996-12-10 1998-06-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
CA2334299A1 (en) 1998-06-05 1999-12-09 Pierre Dextraze Heterocyclic cis cyclopropane derivatives as melatonergic agents
AU763963B2 (en) 1999-06-30 2003-08-07 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
EP1467986A1 (en) * 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
RU2401831C2 (ru) 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276051A (en) * 1991-08-13 1994-01-04 Adir Et Compagnie Arylethylamine compounds
EP0788795A1 (en) * 1994-06-10 1997-08-13 Nauchno-Issledovatelsky Institut Farmakologii Akademii Meditsinskikh Nauk Pharmacologically active 2-mercaptobenzimidazole derivatives
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
CN1922141A (zh) * 2004-02-23 2007-02-28 大日本住友制药株式会社 新的杂环化合物
WO2008032164A2 (en) * 2006-09-12 2008-03-20 Pfizer Products Inc. Benzimidazolone derivatives
WO2008051533A2 (en) * 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Benzimidazole compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neuroreceptor mechanisms involved in the action of afobazole.;Seredenin, S. B.等;《Eksperimental"naya i Klinicheskaya Farmakologiya》;20091231;第72卷(第1期);3-11 *

Also Published As

Publication number Publication date
EP3741760C0 (en) 2024-12-04
ECSP19032963A (es) 2019-05-31
EP3529234A4 (en) 2020-03-11
BR102016024814A2 (pt) 2018-05-08
AU2017351756B2 (en) 2022-01-27
ES3013994T3 (en) 2025-04-16
KR102594251B1 (ko) 2023-10-25
MX392990B (es) 2025-03-24
SG11201903113TA (en) 2019-05-30
EP3741760A1 (en) 2020-11-25
PE20191046A1 (es) 2019-08-06
EP3529234A1 (en) 2019-08-28
UY40644A (es) 2024-02-29
AR109467A1 (es) 2018-12-12
US10781182B2 (en) 2020-09-22
MX2019004782A (es) 2019-10-09
KR20190066023A (ko) 2019-06-12
UY37334A (es) 2018-04-30
US20190270711A1 (en) 2019-09-05
JP2019537624A (ja) 2019-12-26
SG10202009001TA (en) 2020-10-29
ES2970546T3 (es) 2024-05-29
PT3529234T (pt) 2024-02-01
BR112019008197A2 (pt) 2019-07-16
CA3042040A1 (en) 2018-05-03
JP7194683B2 (ja) 2022-12-22
CN110088092A (zh) 2019-08-02
EP3529234B1 (en) 2023-11-29
CO2019004756A2 (es) 2019-05-21
FI3529234T3 (fi) 2023-12-28
EP3741760B1 (en) 2024-12-04
CL2019001105A1 (es) 2019-09-06
US11091445B2 (en) 2021-08-17
PE20250558A1 (es) 2025-02-24
AU2017351756A1 (en) 2019-05-09
WO2018076090A1 (en) 2018-05-03
CN115181108A (zh) 2022-10-14
DK3529234T3 (da) 2024-02-05
US20200277265A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
CN110088092B (zh) 化合物，制备方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法
US8389544B2 (en) Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
Tokunaga et al. Oxindole derivatives as orally active potent growth hormone secretagogues
Kaila et al. Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists
EP1836166B1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP2005529165A (ja) ４−（アリール又はヘテロアリール）−２−ブチルアミン誘導体及びそのグルココルチコイドリガンドとしての使用
JPH05501540A (ja) Ｐｃｐレセプター・リガンドおよびその用途
WO2009100120A2 (en) Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines
JP2022511269A (ja) シャペロン介在性オートファジー調節剤として有用な化合物
HK40081925A (en) Compounds, and preparation process, pharmaceutical composition and use thereof
Li et al. Design, synthesis, and Biological evaluation of phenol Bioisosteric Analogues of 3-Hydroxymorphinan
HK40011198B (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
HK40011198A (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
CN118119617A (zh) 一种双重拮抗剂及其用途
CN110511174A (zh) 一种吲哚烷基哌嗪类化合物及其应用
BR112019008197B1 (pt) Composto, processo de obtenção do composto, composição farmacêutica e uso do composto
Badavath et al. Monoamine oxidase-A inhibitory activity of novel Curcumin analogues
Senthil Kumar et al. Modulation of indole ring annulation in ergoline template: chemistry, receptor binding and in vivo pharmacology with 6-OHDA model of Parkinson’s disease
WO2019029613A1 (zh) 一种氘代喹啉化合物及其制备和用途
Leopoldo et al. In Vitro and In Vivo Evaluation of N‐{2‐[4‐(3‐Cyanopyridin‐2‐yl) piperazin‐1‐yl] ethyl}‐3‐[11C] methoxybenzamide, a Positron Emission Tomography (PET) Radioligand for Dopamine D4 Receptors, in Rodents
Harel et al. New combination of pharmacophoric elements of potent σ1 ligands: Design, synthesis and σ receptor affinity of aminoethyl substituted tetrahydrobenzothiophenes
Fanini Synthesis and Chemical Optimization of New Melatonergic Ligands, including Multitarget Compounds
IL322951A (en) Hydroxyalkyl and methoxyalkyl-modified tryptamines
Jayaprakash et al. Journal of Pharmaceutical Chemistry

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011198

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant